Intelligence Profile
Safety Profile
Evidence Limitations: The available evidence on LL-37 safety is extremely limited. The provided studies are primarily observational research examining LL-37's biological roles and mechanisms rather than formal safety assessments of LL-37 as a therapeutic intervention. No completed clinical trials specifically testing LL-37 administration for safety outcomes were identified.
Known Side Effects:
Direct safety data for LL-37 administration is not available in the provided evidence. One study mentions that LL-37 can generate "rosacea-like skin inflammation," suggesting potential for inflammatory skin reactions, though this appears to be in the context of endogenous LL-37 activity rather than exogenous administration.
Contraindications:
No specific contraindications are established based on the available evidence.
Drug Interactions:
No drug interactions are documented in the provided studies.
Special Populations:
The evidence does not provide specific guidance on populations that should avoid LL-37. However, given the limited safety data, particular caution would be warranted in vulnerable populations such as pregnant women, children, and immunocompromised patients.
Clinical Trial Safety:
While several clinical trials examined LL-37 levels as biomarkers (including studies in smokers, HIV patients, and ICU patients), none involved direct LL-37 administration, so no safety data from therapeutic use is available.
Important Safety Considerations:
The severe lack of safety data represents a significant knowledge gap. Any therapeutic use of LL-37 would require comprehensive safety evaluation through properly designed clinical trials before clinical application.
Disclaimer: This information is for educational purposes only and does not constitute medical advice. Any consideration of LL-37 for therapeutic use should involve consultation with qualified healthcare professionals and appropriate regulatory oversight given the limited safety data available.